Compare Boston Scientific Corporation (BSX) vs CSX Corporation (CSX) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

CSX trades at $50.27, down 0.85% on the day, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and 17% operating income increase. The company raised 2026 guidance to mid-to-high-single-digit revenue growth and margin expansion. Analyst consensus is bullish with 59% buy ratings and a $52.57 price target, implying 4.6% upside from current levels.

Outlook remains positive due to strong volume growth and operational efficiency, but risks include fuel cost pressures and economic sensitivity. The stock offers value through consistent dividends and earnings momentum, though valuation multiples appear elevated with P/E at 29.23. Investors should monitor execution against raised guidance and industry headwinds.